CenTauR: Toward a universal scale and masks for standardizing tau imaging studies

INTRODUCTION: Recently, an increasing number of tau tracers have become available. There is a need to standardize quantitative tau measures across tracers, supporting a universal scale. We developed several cortical tau masks and applied them to generate a tau imaging universal scale. METHOD: 1045 participants underwent tau scans with either 18F-Flortaucipir, 18F-MK6240, 18F-PI2620, 18F-PM-PBB3, 18F-GTP1 or 18F-RO948. The mask was generated from cognitively unimpaired A{beta}- subjects and AD patients with A{beta}+. Four additional regional cortical masks were defined within the constraints of the global mask. A universal scale, the CenTauRz, was constructed. RESULTS: None of the regions known to display off-target signal were included in the masks. The CenTauRz allows robustly discrimination between low and high levels of tau deposits. DISCUSSION: We constructed several tau-specific cortical masks for the AD continuum and a universal standard scale designed to capture the location and degree of abnormality that can be applied across tracers and across centres.

[1]  Joanne S. Robertson,et al.  Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease , 2022, Journal of Alzheimer's disease : JAD.

[2]  D. Minhas,et al.  Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects , 2021, The Journal of Nuclear Medicine.

[3]  Joanne S. Robertson,et al.  Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease , 2021, Journal of Alzheimer's disease reports.

[4]  Philip S. Insel,et al.  A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Sterling C. Johnson,et al.  Four distinct trajectories of tau deposition identified in Alzheimer’s disease , 2021, Nature Medicine.

[6]  C. Rowe,et al.  Relationship between amyloid and tau levels and its impact on tau spreading , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Keith A. Johnson,et al.  Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation , 2020, Neurology.

[8]  D. Minhas,et al.  What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies , 2020, The Journal of Nuclear Medicine.

[9]  Muhammad Naveed Iqbal Qureshi,et al.  18F-MK-6240 PET for early and late detection of neurofibrillary tangles. , 2020, Brain : a journal of neurology.

[10]  O. Hansson,et al.  Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders , 2020, JAMA neurology.

[11]  Val J Lowe,et al.  Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. , 2020, JAMA neurology.

[12]  H. Braak,et al.  To stage, or not to stage , 2019, Current Opinion in Neurobiology.

[13]  Marc D. Normandin,et al.  Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  C. Rowe,et al.  AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON THE BRAIN SURFACE , 2019, Alzheimer's & Dementia.

[15]  L. Dinkelborg,et al.  Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  William J. Jagust,et al.  Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span , 2019, The Journal of Nuclear Medicine.

[17]  M. Mintun,et al.  Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging. , 2019, Journal of Alzheimer's disease : JAD.

[18]  B. Miller,et al.  Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.

[19]  D. Wong,et al.  Evaluation of 18F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain , 2018, The Journal of Nuclear Medicine.

[20]  Christopher G Schwarz,et al.  Longitudinal tau PET in ageing and Alzheimer’s disease , 2018, Brain : a journal of neurology.

[21]  M. Körner,et al.  Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography. , 2017, Journal of medicinal chemistry.

[22]  M. Mintun,et al.  Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects , 2017, The Journal of Nuclear Medicine.

[23]  W. Vanduffel,et al.  Preclinical Evaluation of 18F-JNJ64349311, a Novel PET Tracer for Tau Imaging , 2017, The Journal of Nuclear Medicine.

[24]  Clifford R. Jack,et al.  Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition , 2016, Alzheimer's & dementia.

[25]  Talakad G. Lohith,et al.  Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs). , 2016, Journal of medicinal chemistry.

[26]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[27]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[28]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[29]  Allen F. Brooks,et al.  High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. , 2014, ACS chemical neuroscience.

[30]  C. Rowe,et al.  Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.

[31]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[32]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.

[33]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[34]  Elizabeth C Mormino,et al.  Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant , 2012, NeuroImage.

[35]  W. Jagust Amyloid imaging: liberal or conservative? Let the data decide. , 2011, Archives of neurology.

[36]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[37]  S. Cullum Dementia (2nd edn) , 2001, British Journal of Psychiatry.

[38]  A. Delacourte,et al.  The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.

[39]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.